

McLeod Health

Vedolizumab (Entyvio) Treatment Plan

Patient Name: _____ DOB: _____

Height (cm): _____ Weight (kg): _____ Allergies: _____

Patient Primary Phone Number: _____

Diagnosis (select one and complete the 2nd and 3rd digits to complete the ICD-10 code):

- | | |
|---|---|
| <input type="checkbox"/> K50.0___ Crohn's Disease (small intestine) | <input type="checkbox"/> K51.8___ Other Ulcerative (Chronic) Colitis |
| <input type="checkbox"/> K50.1___ Crohn's Disease (large intestine) | <input type="checkbox"/> K51.5___ Left Sided Ulcerative (Chronic) Colitis |
| <input type="checkbox"/> K50.8___ Crohn's Disease (small & large intestine) | <input type="checkbox"/> K51.0___ Universal Ulcerative (Chronic) Pancolitis |
| <input type="checkbox"/> K50.9___ Crohn's Disease, unspecified | <input type="checkbox"/> K51.9___ Ulcerative Colitis, unspecified |
| <input type="checkbox"/> Other: ICD 10 Code: _____ Diagnosis Description: _____ | |

Pre-Medications: **administered 30 minutes prior to infusion**

- ☐ Acetaminophen 650 mg PO
- ☐ Diphenhydramine: Dose: ☐ 25 mg ☐ 50 mg Route: ☐ PO or ☐ IVP
- ☐ Methylprednisolone: Dose: ☐ 40 mg or ☐ 125 Route: IVP
- ☐ Famotidine: Dose: 20 mg Route: ☐ PO or ☐ IVPB
- ☐ Other (include drug, dose, and route): _____

Drug Orders:

- Vedolizumab (Entyvio) (J3380) 300 mg per 250 mL Sodium Chloride 0.9% IV to infuse over 30 minutes
- Frequency: ☐ Induction: Weeks 0, 2, and 6 then every 8 weeks thereafter
☐ Maintenance: every 8 weeks
☐ Other: _____
- Order Duration: One year unless otherwise specified (Other: _____)

Lab Orders:

☐ _____

Standing Orders:

- Infusion Reaction Protocol (CPOE-1396) will be activated if any hypersensitivity reaction occurs, including anaphylaxis. Infusion will be stopped and physician notified.
- Appropriate access and line care orders per health system policy

Physician Signature: _____ Date: _____

Physician Name: _____ Phone: _____

Pre-Screening Requirements:

- Provide TB screening results (PPD or QuantiFERON Gold Test) prior to start of therapy and within last 12 months
- Provide Hepatitis screening (Hepatitis B Surface Antigen) prior to start of therapy and within last 12 months

Previous Therapies:

- For new patient referrals, please send history and physical and most recent physician note with completed plan
- If patient has previously received vedolizumab at another facility, please provide last date received: _____
- If patient has previously received another biologic therapy, please provide the name: _____
and the last date received: _____

Insurance Information:

Insurance Plan Name: _____

Insurance Identification Number: _____

Insurance Customer Service Contact Number: _____

Preferred Treatment Location

- ☐ McLeod Regional Medical Center (Florence) ☐ McLeod Health Loris ☐ McLeod Health Cheraw
☐ McLeod Health Seacoast (Little River) ☐ McLeod Health Dillon ☐ McLeod Health Clarendon (Manning)

Fax completed Treatment Plan to the McLeod Medication Access Team at 843-777-9798. For any questions, please contact our team at medicationaccessteam@mcleodhealth.org.